CA2495398A1 - Modulation antisens de l'expression de nav1.3 - Google Patents

Modulation antisens de l'expression de nav1.3 Download PDF

Info

Publication number
CA2495398A1
CA2495398A1 CA002495398A CA2495398A CA2495398A1 CA 2495398 A1 CA2495398 A1 CA 2495398A1 CA 002495398 A CA002495398 A CA 002495398A CA 2495398 A CA2495398 A CA 2495398A CA 2495398 A1 CA2495398 A1 CA 2495398A1
Authority
CA
Canada
Prior art keywords
seq
antisense compound
antisense
acid
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002495398A
Other languages
English (en)
Inventor
Steven L. Roberds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia Corporation
Steven L. Roberds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corporation, Steven L. Roberds filed Critical Pharmacia Corporation
Publication of CA2495398A1 publication Critical patent/CA2495398A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
CA002495398A 2002-08-14 2003-08-14 Modulation antisens de l'expression de nav1.3 Abandoned CA2495398A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40341602P 2002-08-14 2002-08-14
US60/403,416 2002-08-14
PCT/US2003/025465 WO2004016754A2 (fr) 2002-08-14 2003-08-14 Modulation antisens de l'expression de nav1.3

Publications (1)

Publication Number Publication Date
CA2495398A1 true CA2495398A1 (fr) 2004-02-26

Family

ID=31888234

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002495398A Abandoned CA2495398A1 (fr) 2002-08-14 2003-08-14 Modulation antisens de l'expression de nav1.3

Country Status (7)

Country Link
EP (1) EP1578927A2 (fr)
JP (1) JP2006507808A (fr)
AU (1) AU2003268096A1 (fr)
BR (1) BR0313455A (fr)
CA (1) CA2495398A1 (fr)
MX (1) MXPA05001836A (fr)
WO (1) WO2004016754A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1687410A4 (fr) 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc Oligonucleotides antisens optimises pour cibler le rein
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
GB0719367D0 (en) 2007-10-03 2007-11-14 Procarta Biosystems Ltd Transcription factor decoys, compositions and methods
BRPI0820391A2 (pt) 2007-11-09 2015-05-19 Isis Pharmaceutical Inc Composto, composição e métodos de modulação da expressão do fator 7
JP2011502515A (ja) * 2007-11-09 2011-01-27 アイシス ファーマシューティカルズ インコーポレイティッド 第９因子発現の調節
GB0906130D0 (en) * 2008-10-03 2009-05-20 Procrata Biosystems Ltd Transcription factor decoys
CN102781480B (zh) * 2009-12-23 2018-07-27 库尔纳公司 通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
GB201002413D0 (en) 2010-02-12 2010-03-31 Procarta Biosystems Ltd Nucleic acid complexes
GB201005545D0 (en) 2010-04-01 2010-05-19 Procarta Biosystems Ltd Transcription factor decoys
PT2585596T (pt) 2010-06-23 2021-03-23 Curna Inc Tratamento de doenças relacionadas com a subunidade alfa de canais de sódio dependentes de voltagem (scna) por inibição da transcrição antissentido natural para scna
ES2688831T3 (es) 2012-06-25 2018-11-07 Ionis Pharmaceuticals, Inc. Modulación de la expresión de UBE3A-ATS
WO2014090985A1 (fr) * 2012-12-13 2014-06-19 Universität Leipzig Modulation des lymphocytes t par saut d'exon
WO2016086104A1 (fr) 2014-11-25 2016-06-02 Ionis Pharmaceuticals, Inc. Modulation de l'expression du ube3a-ats
EP3374509B1 (fr) 2015-11-12 2020-12-16 H. Hoffnabb-La Roche Ag Oligonucléotides pour induire l'expression paternelle d'ube3a
TWI809004B (zh) * 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
JP7476199B2 (ja) * 2018-08-20 2024-04-30 ロジコン， インコーポレイテッド Ｓｃｎ１ａ脳症の治療のためのｓｃｎ２ａを標的とするアンチセンスオリゴヌクレオチド
PE20220284A1 (es) 2019-03-29 2022-02-25 Ionis Pharmaceuticals Inc Compuestos y metodos para modular ube3a-ats

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6124133A (en) * 1999-10-15 2000-09-26 Isis Pharmaceuticals Inc. Antisense inhibition of fra-1 expression
WO2003025188A1 (fr) * 2001-09-14 2003-03-27 Oxford Biomedica (Uk) Limited Utilisation d'un systeme vecteur lentiviral dans le traitement de la douleur

Also Published As

Publication number Publication date
MXPA05001836A (es) 2005-04-19
JP2006507808A (ja) 2006-03-09
BR0313455A (pt) 2007-07-31
AU2003268096A8 (en) 2004-03-03
EP1578927A2 (fr) 2005-09-28
AU2003268096A1 (en) 2004-03-03
WO2004016754A2 (fr) 2004-02-26
WO2004016754A3 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
US6365354B1 (en) Antisense modulation of lysophospholipase I expression
US6426220B1 (en) Antisense modulation of calreticulin expression
AU770526B2 (en) Antisense modulation of PI3K P85 expression
EP1325019B1 (fr) Modulation antisens de l'expression de la clusterine
US6046321A (en) Antisense modulation of G-alpha-i1 expression
US20030083295A1 (en) Antisense modulation of caspase 3 expression
US20020147165A1 (en) Antisense modulation of calreticulin expression
JP2003503048A (ja) Ｓｈｉｐ−２発現のアンチセンスモジュレーション
EP1556509A2 (fr) Modulation anti-sens de l'expression de la chimiokine-1 coregulee par le facteur de croissance endotheliale vasculaire (vegf)
CA2495398A1 (fr) Modulation antisens de l'expression de nav1.3
US5948680A (en) Antisense inhibition of Elk-1 expression
US6379960B1 (en) Antisense modulation of damage-specific DNA binding protein 2, p48 expression
WO2004028458A2 (fr) Modulation antisens de l'expression de synthetase de prostaglandine e2 microsomale
AU2001229537B2 (en) Antisense modulation of macrophage migration inhibitory factor expression
US20030211610A1 (en) Antisense inhibition of adam10 expression
WO2003099215A2 (fr) Modulation antisens de l'expression du recepteur de glucocorticoide
EP1543159A2 (fr) Modulation antisens de l'expression de la molecule endotheliale 1 (esm-1)
US6180353B1 (en) Antisense modulation of daxx expression
US5985664A (en) Antisense modulation of Sentrin expression
US6306655B1 (en) Antisense inhibition of C/EBP alpha expression
US6107092A (en) Antisense modulation of SRA expression
WO2004016749A2 (fr) Modulation antisens de l'expression de l'acyl-coa synthetase 1
WO2004003201A2 (fr) Modulation antisens de l'expression de lrh1
US6451538B1 (en) Antisense modulation of CHK2 expression
WO2002020550A1 (fr) Modulation antisens de l'expression de mekk3

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead